Taking a Closer Look at Probiotic Efficacy

Slides:



Advertisements
Similar presentations
Pharmacological management of delirium
Advertisements

Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.
Upfront Combination Therapy vs Step-Up Approach for PAH:
Wan-Jie Gu, MSc, Chun-Yin Wei, MSc, Rui-Xing Yin, MD, PhD  CHEST 
Introduction to Evidence- Based Practice
Volume 152, Issue 8, Pages e9 (June 2017)
Why Gene Therapy for Hemophilia?
Making Decisions With Your Osteoarthritis Patients
Gout Management.
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
David J.A. Jenkins et al. JACC 2018;71:
A New Era for NOACs:.
The HCV Revolution: Are You and Your Practice Ready?
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Update on Clostridium difficile Infection
Volume 152, Issue 8, Pages e9 (June 2017)
Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.
Comparing Treatment Alternatives in Ankylosing Spondylitis
nAMD: Switching Therapies - what you need to know
DENGUE VACCINE.
Approaches for Cardiologists in the Era of the Affordable Care Act
Managing RA: Telepartnership Between PCP and Rheumatologist
Chronic Idiopathic Urticaria
Volume 152, Issue 8, Pages e9 (June 2017)
Immunization Against Varicella:
The State of Pneumococcal Disease Prevention
Translating Atopic Dermatitis
Exploring Personalized Prophylaxis in Hemophilia A
CPCRN Mission To accelerate the adoption of evidence-based cancer prevention and control in communities.
Optimizing Outcomes and Managing Adverse Events in CLL
Probiotics in the Prevention of C Difficile Infection
Perspectives on the Impact of Inflammation in OA
Battling Constipation
Clinical Recognition and Treatment of Levodopa-Induced Dyskinesia
Simplifying Insulin Delivery for Better Patient Outcomes in T2D
New Recommendations on How to Stage Hidradenitis Suppurativa
Diabetes and Cardiovascular Disease Risk: The Hard Truth
When Is Biologic Therapy Appropriate for HS?
The Primary Care Guide to New CGM Devices and the AGP
Diabetes and Cardiovascular Disease Risk: The Hard Truth
Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.
* * * * * * * * * Form H: Hospital-based data by surveillance period
The Evolving Treatment Landscape in Atopic Dermatitis
Providing Hope and Opportunity
When to Start and What to Use
Introduction to public health surveillance
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
A Time for Change for Managing Patients With VTE Who Have Cancer
Management of Systemic Lupus Erythematosus
Immunization Throughout the Life Course: What Is the Clinician's Role?
Transitional Care of Patients With Hepatic Encephalopathy
Optimizing Joint Health in Hemophilia
Updates in RA, PsA, and Biosimilars
An Unmet Need.
Component 1: Introduction to Health Care and Public Health in the U.S.
The Nurse View: Spotlight on EGFR-Mutated NSCLC
Our Community Where is …?.
Antiarrhythmic Drugs in AF
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
Volume 152, Issue 8, Pages e9 (June 2017)
Patient and Clinician Perspectives on Preventive Therapy for Migraine
New Options for the Treatment of Hepatocellular Carcinoma
Empowering Patients and Prescribers to Improve Treatment Adherence in Schizophrenia.
What's New in Oral Combination Therapy for Type 2 Diabetes?
Contribution of Vaccines to Life-Course Event-Free Health
Comparative Studies of Biologics in Ulcerative Colitis
Biosimilars in Immune-Related Diseases
Shifting the Paradigm.
Fig. 3. Strategy for the development of probiotics as prophylactic and therapeutic microbial agent. More stress should be laid on strain specificity and.
Presentation transcript:

Taking a Closer Look at Probiotic Efficacy

Medscape attempts to use generic names for tests whenever possible Medscape attempts to use generic names for tests whenever possible. In this program, the trade names for probiotics are used for clarity. The use of trade names should not be viewed as an endorsement by Medscape of specific products.

Introduction to Probiotics

Reasons for Misconceptions About Probiotics

Myth: All Probiotics Are the Same

Systematic Review and Meta-Analysis on Assessing Strain- and Disease-Specific Efficacy

Evidence-Based Guide on Choosing an Appropriate Probiotic Product

Grading of Efficacy Evidence

Evidence for AAD and CDI

Limitations of Studies on Probiotic Products

CDI-Associated Diarrhea

Cochrane Review on Probiotics for the Prevention of CDI-Associated Diarrhea

Findings of Cochrane Review

Primary or Secondary Prevention of CDI

Real-World Studies Reducing Incidence of CDI in Hospitals With Probiotics

Use of Probiotics as Primary Prevention of CDI at a Community Hospital

Use of Probiotics as Primary Prevention of CDI at a Community Hospital

Using Probiotics in a Bundled Approach

Recommending Probiotics to Patients

Concluding Remarks

Abbreviations